Baxter BioScience starts construction of $50 million expansion at their Thousand Oaks, California campus, in an Advisory by Industrialinfo.com
Baxter BioScience's Thousand Oaks facility manufactures recombinant Antihemophilic Factor (rAHF), which is a clotting factor produced by recombinant DNA technology and used as a treatment for the blood disorder hemophilia. Baxter has just received FDA approval on Suite C, a third production suite that was completed earlier this year. Suite C had been in full production prior to the FDA notification, having already received European regulatory approval.
Global demand for hemophilia therapy has doubled since 1985, due in part to increased preventive treatment. Baxter has increased its North American rAHF capacity every year since its introduction in 1992 and anticipates a global capacity of two billion units of rAHF by 2005.
Baxter Healthcare Corporation is the principal U.S. operating subsidiary of Baxter International Incorporated. Baxter is a global medical products and services company that provides treatment therapies for people with life-threatening conditions in more than 100 countries. Baxter employs over 45,000 employees and had $6.9 billion in total sales for 2000.
Industrialinfo.com provides daily news related to the industrial market place including industry alerts and databases for the energy and industrial markets. For more information on trends and upcoming construction activities in the Chemical and Pharmaceutical industry as well as other industrial sectors send inquiries to chemicalsgroup@industrialinfo.com or visit us at www.industrialinfo.com.